WO2017111215A1 - 기억력, 학습력, 인지력 향상용 조성물 - Google Patents
기억력, 학습력, 인지력 향상용 조성물 Download PDFInfo
- Publication number
- WO2017111215A1 WO2017111215A1 PCT/KR2016/004650 KR2016004650W WO2017111215A1 WO 2017111215 A1 WO2017111215 A1 WO 2017111215A1 KR 2016004650 W KR2016004650 W KR 2016004650W WO 2017111215 A1 WO2017111215 A1 WO 2017111215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- memory
- amino acid
- disease
- cognitive
- Prior art date
Links
- 230000015654 memory Effects 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000013016 learning Effects 0.000 title claims abstract description 9
- 230000019771 cognition Effects 0.000 title abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 14
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 208000026139 Memory disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 230000001149 cognitive effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 201000003723 learning disability Diseases 0.000 claims description 7
- 206010027175 memory impairment Diseases 0.000 claims description 7
- 208000020358 Learning disease Diseases 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 230000003925 brain function Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 230000003920 cognitive function Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010073306 Exposure to radiation Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 210000001652 frontal lobe Anatomy 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000003906 hydrocephalus Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 230000006984 memory degeneration Effects 0.000 claims description 3
- 208000023060 memory loss Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000001320 hippocampus Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000007087 memory ability Effects 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 150000001413 amino acids Chemical class 0.000 abstract description 16
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 23
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 23
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 23
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 23
- 229960002646 scopolamine Drugs 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000007787 long-term memory Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000006993 memory improvement Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 101710176384 Peptide 1 Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011302 passive avoidance test Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003935 attention Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009225 memory damage Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to a composition for improving memory, learning, and cognition.
- the brain has many functions, but the most important ones are memory and cognition. If human beings do not have cognitive and memory skills, it is difficult for them to carry out their daily activities and they are a problem for their survival. Memory and cognition are associated with almost every function of the brain, and the brain structures involved in memory and cognition are diverse and closely linked to almost all brain parts.
- Coding is the first process in which information entered into the brain through the sense organs is learned and memorized. Although information is stored once through encoding, in order to keep the stored information continuously and to store it with more robust memory, it is necessary to go through the encoding process. This process is called coagulation. If memory is not coagulated well, forgetting of memory occurs quickly and it is difficult to maintain memory. Withdrawal is the process of consciously recalling the contents stored in long-term memory. There are two ways to withdraw: recollection and acknowledgment. Recall is to consciously recall the contents of memory, and jane is to call it with hints. In most cases, recall is harder than recognition.
- Short-term memory is also called working memory, which refers to the process of storing information for a short period of time and then performing the next task.
- the information that enters the brain stays temporarily before it hardens into long-term memory.
- the characteristic of working memory is that after performing a certain work, the working memory is usually erased.
- Memory and cognitive impairments are very serious conditions that make life impossible, including aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Peak disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral ischemia, encephalitis, forgetfulness, traumatic brain injury, hypoglycemia, Wernicke Korsakov syndrome, drug addiction, epilepsy, epilepsy, hippocampus, headache, cerebral senile dysfunction, dementia, prefrontal degeneration, tumors, normal hydrocephalus, HIV , Cerebrovascular disease, cranial nerve disease, cardiovascular disease, memory loss, radiation exposure, metabolic disease, hypothyroidism, mild cognitive impairment, cognitive deficit or attention
- an object of the present invention is to provide a peptide for improving memory, learning, cognition.
- the present invention provides a peptide wherein the C-terminal portion comprises the amino acid sequence of GAG.
- the peptide is preferably derived from the hydrolyzate of silk fibroin, but is not limited thereto.
- the peptide is preferably artificially synthesized, but is not limited thereto.
- the peptide is preferably 4 to 6 amino acid residues number is not limited to the length, the peptide is preferably amino acid sequence GGAG, AGAG, QGAG, or SGAGAG amino acid It is not limited to the sequence.
- the peptide is preferably an amino acid residue number of 5 to 9, the peptide is preferably an amino acid sequence of QAGAG, SGGAG, or GAGGAGGAG, but is not limited thereto.
- the peptides of the present invention exhibit excellent stability on their own, but various protection groups can be combined to further improve the stability.
- protecting groups include amino acids, acetyl groups, fluorenyl methoxy carbonyl groups, formyl groups, palmitoyl groups, myristyl groups, stearyl groups, and polyethylene glycol (PEG).
- the protecting group may be attached to various amino acid residues of the peptide of the present invention, but is preferably bonded to the N- or C-terminus.
- the present invention provides a pharmaceutical composition for preventing or treating memory, cognitive or learning disorders, comprising the peptide of the present invention as an active ingredient.
- the memory, cognitive or learning disorders are aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Peak disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia , Cerebral ischemia, encephalitis, forgetfulness, traumatic brain injury, hypoglycemia, Wernicke Korsakoff syndrome, drug addiction, epilepsy, epilepsy, hippocampal sclerosis, headache, cerebral senile disease, dementia, frontal lobe degeneration, tumor, normal brain hydrocephalus, HIV, Cerebrovascular disease, cerebral nerve disease, cardiovascular disease, memory loss, radiation exposure, metabolic disease, hypothyroidism, mild cognitive impairment, cognitive deficit and attention deficit due to memory, cognitive or learning disorders, but is not limited thereto.
- the composition may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers included in the composition are conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, fine Crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the pharmaceutical composition may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like, in addition to the above components.
- the pharmaceutical composition may be administered orally or parenterally.
- parenteral administration it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, endothelial administration, topical administration, nasal administration, pulmonary administration and rectal administration.
- the protein or peptide When orally administered, the protein or peptide is digested so that the oral composition can be formulated to coat the active agent or protect it from degradation in the stomach.
- the composition may be administered by any device in which the active substance may migrate to the target cell.
- Appropriate dosages of the pharmaceutical compositions can be prescribed in various ways, such as by the method of formulation, mode of administration, age, weight, sex, morbidity, patient's age, food, time of administration, route of administration, rate of excretion and response to reaction. have. Preferred dosages of the compositions are in the range of 0.001-100 mg / kg on an adult basis.
- pharmaceutically effective amount means an amount sufficient to prevent or treat memory impairment, cognitive impairment or learning disability.
- the composition may be prepared in unit dose form or formulated into a multi-dose container by formulating with a pharmaceutically acceptable carrier and / or excipient, according to methods readily available to those skilled in the art.
- the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.
- the composition may be administered as a separate therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.
- the present invention provides a food composition for enhancing the brain or cognitive function comprising the peptide of the present invention as an active ingredient.
- the brain or cognitive function is preferably, but not limited to, learning ability, memory ability or concentration.
- the amount of the peptide in the food or beverage of the present invention may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1g based on 100 ml. However, this can be easily determined by those skilled in the art to suit the product.
- the food composition may further include food supplements that are food acceptable, and may be prepared in the form of tablets, capsules, pills, liquids, jelly, powders, granules, and the like.
- the food composition of the present invention is not particularly limited to other ingredients except for containing the peptide as an essential ingredient, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
- natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents such as, tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
- the proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
- the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
- the food composition of the present invention may contain a fruit flesh for producing natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the compound of the present invention.
- the present invention also provides a polynucleotide encoding the peptide of the present invention.
- polynucleotide is a polymer of deoxyribonucleotides or ribonucleotides present in single- or double-stranded form. It encompasses RNA genomic sequences, DNA (gDNA and cDNA) and RNA sequences transcribed therefrom and includes analogs of natural polynucleotides unless specifically stated otherwise.
- the polynucleotide includes not only the nucleotide sequence but also a sequence complementary to the sequence.
- Such complementary sequences include sequences that are substantially complementary, as well as sequences that are substantially complementary. This means a sequence that can hybridize with the nucleotide sequence under stringent conditions known in the art.
- the polynucleotide may also be modified. Such modifications include addition, deletion or non-conservative substitutions or conservative substitutions of nucleotides.
- the polynucleotide encoding the amino acid sequence is to be interpreted to also include a nucleotide sequence showing substantial identity to the nucleotide sequence. The substantial identity is at least 80% homology when the nucleotide sequence is aligned with any other sequence as closely as possible and the aligned sequence is analyzed using algorithms commonly used in the art. A sequence exhibiting at least 90% homology or at least 95% homology.
- the present invention also provides a recombinant vector comprising the polynucleotide of the present invention.
- vector means a means for expressing a gene of interest in a host cell.
- viral vectors such as plasmid vectors, cosmid vectors and bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors are included.
- Vectors that can be used as the recombinant vector are plasmids often used in the art (eg, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14).
- phages eg, ⁇ gt4 ⁇ B, ⁇ -Charon, ⁇ z1 and M13, etc.
- viruses eg, CMV, SV40, etc.
- the polynucleotide encoding the peptide in the recombinant vector may be operably linked to a promoter.
- operatively linked means a functional bond between a nucleotide expression control sequence (eg, a promoter sequence) and another nucleotide sequence.
- a nucleotide expression control sequence eg, a promoter sequence
- the regulatory sequence can thereby regulate transcription and / or translation of the other nucleotide sequence.
- the recombinant vector can typically be constructed as a vector for cloning or a vector for expression.
- the expression vector may be a conventional one used in the art to express foreign proteins in plants, animals or microorganisms.
- the recombinant vector may be constructed through various methods known in the art.
- the recombinant vector may be constructed using prokaryotic or eukaryotic cells as hosts.
- a strong promoter for example, a pL ⁇ promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.
- replication origins that operate in eukaryotic cells included in the vector include f1 origin, SV40 origin, pMB1 origin, adeno origin, AAV origin, CMV origin, and BBV origin.
- promoters derived from the genome of mammalian cells eg, metallothionine promoters
- promoters derived from mammalian viruses eg, adenovirus late promoters, vaccinia virus 7.5K promoters, SV40 promoters, Cytomegalovirus (CMV) promoter and tk promoter of HSV
- CMV Cytomegalovirus
- the present invention provides a host cell transformed with the recombinant vector of the present invention.
- the host cell of the present invention can use any host cell known in the art, and prokaryotic cells are, for example, E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. strains of the genus Bacillus, such as coli B, E. coli X 1776, E. coli W3110, Bacillus subtilis, Bacillus thuringiensis, and enterococci and strains, such as Salmonella typhimurium, Serratia marsonsons and various Pseudomonas species.
- prokaryotic cells are, for example, E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. strains of the genus Bacillus, such as coli B, E. coli X 1776, E. coli W3110, Bacillus subtilis, Bacillus thuringiensis, and enterococci and strains, such as Salmonella typ
- yeast Sacharomyce cerevisiae
- insect cells plant cells and animal cells
- plant cells and animal cells such as SP2 / 0, Chinese hamster ovary (CHO) K1, CHO DG44, PER. C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN and MDCK cell lines and the like
- CHO Chinese hamster ovary
- PER. C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN and MDCK cell lines and the like can be used.
- the present invention provides a method for producing a peptide of the present invention comprising the step of culturing the host cell of the present invention.
- Insertion of the polynucleotide or a recombinant vector comprising the same into a host cell may use an insertion method well known in the art.
- a CaCl 2 method or an electroporation method may be used.
- a micro-injection method, calcium phosphate precipitation method, electroporation method, liposomes, or the like may be used.
- -Mediated transfection and gene bombardment may be used, but is not limited thereto.
- the method of selecting the transformed host cell can be easily carried out according to methods well known in the art using a phenotype expressed by a selection label.
- the selection marker is a specific antibiotic resistance gene
- the transformant can be easily selected by culturing the transformant in a medium containing the antibiotic.
- the effect of improving the memory of the peptide whose C-terminus ends with GAG was confirmed, and in order for the peptide to have an effect, it was confirmed that the peptide should be a peptide composed of at least 4 amino acids in length. It was confirmed that the peptide consisting of amino acids less than 5 or more than 9 amino acids in length of the C-terminal end GAG, the peptide of the present invention can be used as a composition for improving memory, learning ability, cognition.
- 1 is a diagram showing the memory enhancement effect of the peptide GAG amino acid sequence of the C-terminal region through a passive avoidance experiment.
- y-axis is time in seconds
- Figure 2 is a diagram showing the memory enhancement effect of the peptide GAG amino acid sequence of the C terminal region through the Y maze experiment. y-axis shows change behavior (%)
- FIG. 3 is a diagram showing the memory enhancement effect of the peptide GAG amino acid sequence of the C-terminal region consisting of 5-9 amino acids through passive avoidance experiment.
- Figure 4 is a diagram showing the memory enhancement effect of the peptide GAG amino acid sequence of the C-terminal region consisting of 5-9 amino acids through the Y maze experiment.
- the synthesized peptide was obtained from Genscript (New Jersey, USA). Peptides were synthesized using the Flexpeptide technology method and identified using high performance liquid chromatography and mass spectrometry. The amino acid sequence of the synthesized peptide is shown in Table 1 below.
- the inventors further synthesized the amino acid sequence 5 to 9 peptides (SEQ ID NOS: 7 to 9) to perform additional experiments. These synthesized peptides were obtained from Genscript (New Jersey, USA). Peptides were synthesized using the Flexpeptide technology method and identified using high performance liquid chromatography and mass spectrometry. The amino acid sequence of the synthesized peptide is as follows;
- GAGGAGGAG SEQ ID NO: 9
- Scopolamine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Four-week-old male ICR mice were treated with Korean BioLink Co. It was purchased from (Chungbuk, Korea). After a one week adaptation period, the experiments were used and all reagents were administered intraperitoneally. Memory impairment was induced by the injection of scopolamine 30 minutes before the test, and the synthesized peptide was injected 30 minutes before the injection of scopolamine.
- mice were placed in bright rooms after injection of reagents and the doors opened 10 seconds later. When the mouse completely entered the dark room, the door was closed and an electric shock was applied for 3 seconds.
- a retention trial was performed 24 hours after the acquisition attempt and the mice were placed in a bright room. The latency time of acquisition and retention attempts was measured as the time from the opening of the door to the dark room of the box.
- the response time of saline-treated mice was 180 seconds (maximum cut off time). It was confirmed that the average of the step-through reaction of the scopolamine-injected group in which memory decreased due to the injection of scopolamine was significantly lower than that of the physiological saline group.
- the peptide-1 administration group consisting of two amino acids showed a slight improvement compared to the scopolamine administration group, and the peptide-3 administration group had almost the same effect as the scopolamine administration group.
- the peptide-2 and peptide-4 to 6 groups improved the memory reduced by scopolamine closer to the normal group to which saline was administered. From the above results, the memory-improving effect of the peptide whose C-terminus ends with GAG was confirmed, and in order for the peptide to have an effect, it was confirmed that the peptide should be a peptide composed of at least 4 amino acids in length.
- the response time of saline-treated mice was 180 seconds (maximum cutoff time). It was confirmed that the average of the step-through reaction of the scopolamine-injected group in which memory decreased due to the injection of scopolamine was significantly lower than that of the physiological saline group.
- the peptide administration group consisting of 5-9 amino acids of the present invention prior to the administration of scopolamine it was confirmed that the memory reduced by scopolamine improved closer to the normal group to which saline was administered. From the above results, the memory-improving effect of the peptide whose C-terminal ends with GAG was confirmed.
- mice were placed at one end of the Y labyrinth consisting of 30 cm in length, 5 cm in width, and 13 cm in height, and the order of entry into each branch was recorded. The alteration was judged to be successful when sequentially entered three different branches. Spontaneous alternation is defined by the following equation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Psychology (AREA)
Abstract
Description
펩타이드 명칭(서열번호) | 아미노산 서열 |
펩타이드-1 | AG |
펩타이드-2 | GAG |
펩타이드-3 | AGAG |
펩타이드-4 | QGAG |
펩타이드-5 | GGAG |
펩타이드-6 | SGAGAG |
Claims (17)
- C 말단 부위가 GAG의 아미노산 서열을 포함하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 인공적으로 합성된 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 잔기의 수가 4 내지 6인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 서열이 GGAG인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 서열이 AGAG인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 서열이 QGAG 인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 서열이 SGAGAG인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 아미노산 잔기의 수가 5 내지 9인 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 아미노산 서열이 QAGAG, SGGAG, 또는 GAGGAGGAG인 것 것을 특징으로 하는 펩타이드.
- 제1항 내지 제9항 중 어느 한 항의 펩타이드를 유효성분으로 포함하는, 기억, 인지 또는 학습장애의 예방 또는 치료용 약학적 조성물.
- 제10항에 있어서, 상기 기억, 인지 또는 학습장애는 노화, 알쯔하이머병, 정신분열증, 파킨슨병, 헌팅톤병, 피크병, 크로이츠펠트-야콥병, 우울증, 노화, 두부 외상, 뇌졸중, CNS 저산소증, 뇌 허혈증, 뇌염, 건망증, 외상성 뇌손상, 저혈당증, 베르니케 코르사코프 신드롬, 약물중독, 뇌전증, 간질, 해마경화증, 두통, 뇌 노쇠증, 치매, 전측두엽 변성, 종양, 정상뇌압수두증, HIV, 뇌혈관성질환, 뇌신경질환, 심혈관계 질환, 기억상실, 방사능 노출, 대사성 질환, 갑상선 기능 저하증, 경도인지장애, 인지 결핍 및 주의력 결핍에 의한 기억, 인지 또는 학습장애인 것을 특징으로 하는 약학적 조성물.
- 제1항 내지 제9항 중 어느 한 항의 펩타이드를 유효성분으로 포함하는, 두뇌 또는 인지 기능의 증진을 위한 식품 조성물.
- 제12항에 있어서, 상기 두뇌 또는 인지 기능은 학습 능력, 기억 능력 또는 집중력인 것을 특징으로 하는 식품 조성물.
- 제1항 내지 제9항 중 어느 한 항의 펩타이드를 코딩하는 폴리뉴클레오티드.
- 제14항의 폴리뉴클레오티드를 포함하는 재조합 벡터.
- 제15항의 재조합 벡터로 형질전환된 숙주세포.
- 제16항의 숙주세포를 배양하는 단계를 포함하는 펩타이드의 제조방법.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2018701947A MY197348A (en) | 2015-12-21 | 2016-05-03 | A composition for improving memory, learning ability, and cognitive ability |
TR2018/07610T TR201807610T1 (tr) | 2015-12-21 | 2016-05-03 | Hafizanin, öğrenme beceri̇si̇ni̇n ve bi̇li̇şsel beceri̇ni̇n geli̇şti̇ri̇lmesi̇ i̇çi̇n kompozi̇syon |
SG11201804902UA SG11201804902UA (en) | 2015-12-21 | 2016-05-03 | A composition for improving memory, learning ability, and cognitive ability |
US15/482,752 US20180201645A1 (en) | 2015-12-21 | 2016-05-03 | Composition for improving memory, learning ability, and cognitive ability |
JP2017546737A JP6463499B2 (ja) | 2015-12-21 | 2016-05-03 | 記憶力、学習力、認知力向上用組成物 |
BR112018012527-0A BR112018012527A2 (pt) | 2015-12-21 | 2016-05-03 | composição para melhorar a memória, a capacidade de aprendizado, e a capacidade cognitiva |
CA2965840A CA2965840C (en) | 2015-12-21 | 2016-05-03 | A composition for improving memory, learning ability, and cognitive ability |
CN201680013706.9A CN107406482A (zh) | 2015-12-21 | 2016-05-03 | 记忆力、学习力、认知力提高用组合物 |
RU2018120516A RU2694064C1 (ru) | 2015-12-21 | 2016-05-03 | Композиция для улучшения памяти, способности к обучению и когнитивных способностей |
AU2016376059A AU2016376059B2 (en) | 2015-12-21 | 2016-05-03 | Composition for improving memory, learning ability and cognition |
MX2018006823A MX2018006823A (es) | 2015-12-21 | 2016-05-03 | Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. |
EP16879083.0A EP3255055B1 (en) | 2015-12-21 | 2016-05-03 | Composition for improving memory, learning ability and cognition |
PH12017550079A PH12017550079A1 (en) | 2015-12-21 | 2017-08-11 | Composition for improving memory, learning ability and cognition |
US16/010,473 US20180325980A1 (en) | 2015-12-21 | 2018-06-17 | Composition for improving memory, learning ability, and cognitive ability |
US16/011,637 US10435436B2 (en) | 2015-12-21 | 2018-06-19 | Composition for improving memory, learning ability, and cognitive ability |
US16/011,638 US20180327452A1 (en) | 2015-12-21 | 2018-06-19 | Composition for improving memory, learning ability, and cognitive ability |
AU2019200449A AU2019200449A1 (en) | 2015-12-21 | 2019-01-23 | A composition for improving memory, learning ability and cognitive ability |
US16/270,810 US11369659B2 (en) | 2015-12-21 | 2019-02-08 | Method of enhancing a brain or cognitive function |
US17/825,064 US20220296673A1 (en) | 2015-12-21 | 2022-05-26 | Method of enhancing a brain or cognitive function |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150183011A KR101706296B1 (ko) | 2015-12-21 | 2015-12-21 | 기억력, 학습력, 인지력 향상용 조성물 |
KR10-2015-0183011 | 2015-12-21 | ||
KR10-2016-0026600 | 2016-03-04 | ||
KR1020160026600A KR101844481B1 (ko) | 2016-03-04 | 2016-03-04 | 기억력 향상 효과를 가지는 펩타이드 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/482,752 A-371-Of-International US20180201645A1 (en) | 2015-12-21 | 2016-05-03 | Composition for improving memory, learning ability, and cognitive ability |
US15/893,274 Continuation US20180169179A1 (en) | 2015-12-21 | 2018-02-09 | Composition for improving memory, learning ability, and cognitive ability |
US16/011,638 Division US20180327452A1 (en) | 2015-12-21 | 2018-06-19 | Composition for improving memory, learning ability, and cognitive ability |
US16/011,637 Division US10435436B2 (en) | 2015-12-21 | 2018-06-19 | Composition for improving memory, learning ability, and cognitive ability |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017111215A1 true WO2017111215A1 (ko) | 2017-06-29 |
Family
ID=59090692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/004650 WO2017111215A1 (ko) | 2015-12-21 | 2016-05-03 | 기억력, 학습력, 인지력 향상용 조성물 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20180201645A1 (ko) |
EP (1) | EP3255055B1 (ko) |
JP (1) | JP6463499B2 (ko) |
CN (2) | CN110279845B (ko) |
AU (2) | AU2016376059B2 (ko) |
BR (1) | BR112018012527A2 (ko) |
CA (1) | CA2965840C (ko) |
MX (1) | MX2018006823A (ko) |
MY (1) | MY197348A (ko) |
PH (1) | PH12017550079A1 (ko) |
RU (1) | RU2694064C1 (ko) |
SA (1) | SA518391710B1 (ko) |
SG (1) | SG11201804902UA (ko) |
TR (1) | TR201807610T1 (ko) |
WO (1) | WO2017111215A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743293C1 (ru) * | 2020-07-06 | 2021-02-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение пептида Gly-His-Lys-Val-Glu-Pro для повышения обучаемости и улучшения памяти. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5243038A (en) * | 1986-11-04 | 1993-09-07 | Protein Polymer Technologies, Inc. | Construction of synthetic DNA and its use in large polypeptide synthesis |
US20030176355A1 (en) * | 1994-03-11 | 2003-09-18 | Protein Polymer Technologies, Inc. | Synthetic proteins for in vivo drug delivery and tissue augmentation |
KR100494358B1 (ko) * | 2004-07-30 | 2005-06-10 | 주식회사 바이오그랜드 | 두뇌 또는 인지 기능 증진용 조성물 |
KR100864380B1 (ko) * | 2006-10-17 | 2008-10-21 | 주식회사 브레인가드 | 두뇌기능 향상과 뇌신경계 질환 예방 또는 치료용 펩타이드 |
KR101430387B1 (ko) * | 2014-04-08 | 2014-08-13 | 강용구 | 실크 피브로인 유래 펩타이드, 및 이를 포함하는 기억력, 학습력, 인지력의 향상 또는 치매의 예방 또는 치료용 조성물 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003533A1 (en) | 1986-11-04 | 1988-05-19 | Syntro Corporation | Construction of synthetic dna and its use in large polypeptide synthesis |
GB2285446B (en) * | 1994-01-03 | 1999-07-28 | Genentech Inc | Thrombopoietin |
US6069129A (en) * | 1998-03-13 | 2000-05-30 | Mrs, Llc | Elastin derived composition and method of using same |
EP1104304A1 (en) * | 1998-08-13 | 2001-06-06 | G.D. Searle & Co. | Multivalent avb3 and metastasis-associated receptor ligands |
US6608242B1 (en) | 2000-05-25 | 2003-08-19 | E. I. Du Pont De Nemours And Company | Production of silk-like proteins in plants |
WO2002010430A2 (en) * | 2000-07-31 | 2002-02-07 | Amidut Ltd. | Detecting anti-viral drug candidates and resistance |
CA2439101C (en) * | 2001-02-22 | 2012-07-10 | Zealand Pharma A/S | New medical uses of intercellular communication facilitating compounds |
US7056889B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
CN1532281A (zh) * | 2003-03-21 | 2004-09-29 | 吉林大学第一医院 | 癌胚抗原基因片段的重组及基因疫苗 |
MXPA05012201A (es) * | 2003-05-14 | 2006-02-10 | Dow Corning | Conjugados de agentes activos de polimero de proteina de secuencia de repeticion, metodos y usos. |
US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
KR20070000892A (ko) * | 2005-06-28 | 2007-01-03 | 하성원 | 누에실크 피브로인의 재생방법 |
WO2007019860A2 (en) * | 2005-08-16 | 2007-02-22 | Copenhagen University | Gdnf derived peptides |
EP1960425A2 (en) * | 2005-11-07 | 2008-08-27 | Copenhagen University | Neurotrophin-derived peptide sequences |
EP2036567A3 (en) * | 2005-12-06 | 2009-12-09 | P2-Science APS | Modulation of the P2Y2 receptor pathway |
WO2007124593A1 (en) * | 2006-05-02 | 2007-11-08 | Universite Laval | Branched peptide amplification and uses thereof |
WO2010054319A2 (en) * | 2008-11-10 | 2010-05-14 | Codexis, Inc. | Penicillin-g acylases |
JP2013503634A (ja) * | 2009-09-02 | 2013-02-04 | カンザス ステイト ユニバーシティ リサーチ ファウンデーション | プロテアーゼのmriアッセイおよび光学アッセイ |
US8916679B2 (en) * | 2009-12-01 | 2014-12-23 | Universita′ degli Studi di Modena e Reggio Emilia | Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer |
EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
DK2575846T3 (en) | 2010-05-27 | 2015-08-10 | Janssen Biotech Inc | Insulin-like growth factor-1 receptor binding peptides |
JP2012017287A (ja) * | 2010-07-07 | 2012-01-26 | Iwate Univ | 老齢性疾患治療薬 |
WO2012092718A1 (en) * | 2011-01-07 | 2012-07-12 | Nanjing University | Photo-responsive supramolecular hydrogels |
EP2699692B1 (fr) * | 2011-04-21 | 2016-09-14 | Biomerieux, Inc | Procede de detection d'au moins un mecanisme de resistance aux cephalosporines par spectrometrie de masse |
EP2970416B1 (en) * | 2013-03-15 | 2023-11-22 | Chugh, Sumant S. | Methods for treatment of nephrotic syndrome and related conditions |
KR20150114916A (ko) * | 2014-04-02 | 2015-10-13 | 조아제약주식회사 | 기억력 증진 또는 집중력 향상 조성물 |
-
2016
- 2016-05-03 US US15/482,752 patent/US20180201645A1/en not_active Abandoned
- 2016-05-03 EP EP16879083.0A patent/EP3255055B1/en active Active
- 2016-05-03 MX MX2018006823A patent/MX2018006823A/es unknown
- 2016-05-03 SG SG11201804902UA patent/SG11201804902UA/en unknown
- 2016-05-03 CA CA2965840A patent/CA2965840C/en active Active
- 2016-05-03 TR TR2018/07610T patent/TR201807610T1/tr unknown
- 2016-05-03 BR BR112018012527-0A patent/BR112018012527A2/pt active Search and Examination
- 2016-05-03 AU AU2016376059A patent/AU2016376059B2/en active Active
- 2016-05-03 WO PCT/KR2016/004650 patent/WO2017111215A1/ko active Application Filing
- 2016-05-03 JP JP2017546737A patent/JP6463499B2/ja active Active
- 2016-05-03 CN CN201910592808.6A patent/CN110279845B/zh active Active
- 2016-05-03 CN CN201680013706.9A patent/CN107406482A/zh active Pending
- 2016-05-03 RU RU2018120516A patent/RU2694064C1/ru active
- 2016-05-03 MY MYPI2018701947A patent/MY197348A/en unknown
-
2017
- 2017-08-11 PH PH12017550079A patent/PH12017550079A1/en unknown
-
2018
- 2018-05-31 SA SA518391710A patent/SA518391710B1/ar unknown
- 2018-06-19 US US16/011,637 patent/US10435436B2/en active Active
- 2018-06-19 US US16/011,638 patent/US20180327452A1/en not_active Abandoned
-
2019
- 2019-01-23 AU AU2019200449A patent/AU2019200449A1/en not_active Abandoned
-
2022
- 2022-05-26 US US17/825,064 patent/US20220296673A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5243038A (en) * | 1986-11-04 | 1993-09-07 | Protein Polymer Technologies, Inc. | Construction of synthetic DNA and its use in large polypeptide synthesis |
US20030176355A1 (en) * | 1994-03-11 | 2003-09-18 | Protein Polymer Technologies, Inc. | Synthetic proteins for in vivo drug delivery and tissue augmentation |
KR100494358B1 (ko) * | 2004-07-30 | 2005-06-10 | 주식회사 바이오그랜드 | 두뇌 또는 인지 기능 증진용 조성물 |
KR100864380B1 (ko) * | 2006-10-17 | 2008-10-21 | 주식회사 브레인가드 | 두뇌기능 향상과 뇌신경계 질환 예방 또는 치료용 펩타이드 |
KR101430387B1 (ko) * | 2014-04-08 | 2014-08-13 | 강용구 | 실크 피브로인 유래 펩타이드, 및 이를 포함하는 기억력, 학습력, 인지력의 향상 또는 치매의 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU2019200449A1 (en) | 2019-02-07 |
CN110279845B (zh) | 2021-08-20 |
SG11201804902UA (en) | 2018-07-30 |
TR201807610T1 (tr) | 2018-06-21 |
MX2018006823A (es) | 2018-11-29 |
RU2694064C1 (ru) | 2019-07-09 |
US20180327452A1 (en) | 2018-11-15 |
AU2016376059B2 (en) | 2019-02-14 |
JP6463499B2 (ja) | 2019-02-06 |
BR112018012527A2 (pt) | 2018-12-11 |
CA2965840C (en) | 2021-11-30 |
CN107406482A (zh) | 2017-11-28 |
AU2016376059A1 (en) | 2017-10-05 |
US20180327451A1 (en) | 2018-11-15 |
MY197348A (en) | 2023-06-14 |
SA518391710B1 (ar) | 2022-11-09 |
US20220296673A1 (en) | 2022-09-22 |
EP3255055A4 (en) | 2018-04-18 |
JP2018517394A (ja) | 2018-07-05 |
EP3255055A1 (en) | 2017-12-13 |
US10435436B2 (en) | 2019-10-08 |
US20180201645A1 (en) | 2018-07-19 |
CN110279845A (zh) | 2019-09-27 |
CA2965840A1 (en) | 2017-06-29 |
PH12017550079A1 (en) | 2018-02-12 |
EP3255055B1 (en) | 2024-06-05 |
EP3255055C0 (en) | 2024-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101706296B1 (ko) | 기억력, 학습력, 인지력 향상용 조성물 | |
KR101430387B1 (ko) | 실크 피브로인 유래 펩타이드, 및 이를 포함하는 기억력, 학습력, 인지력의 향상 또는 치매의 예방 또는 치료용 조성물 | |
WO2018080077A1 (ko) | 네오아가로올리고당을 포함하는 관절염 또는 골다공증 예방, 개선 또는 치료용 조성물 | |
WO2017111215A1 (ko) | 기억력, 학습력, 인지력 향상용 조성물 | |
KR101486074B1 (ko) | 골질환 예방 또는 치료용 신규한 펩타이드 및 이의 이용 | |
US11622983B2 (en) | Pharmaceutical composition for preventing or treating neurodegenerative diseases including fermented steam-dried ginseng berry | |
KR101844480B1 (ko) | 기억력 향상 효과를 가지는 펩타이드 | |
KR20190070629A (ko) | HBD2(human beta-defensin 2) 또는 상기 유전자와 융합된 메르스 코르나 바이러스의 에피토프 단백질을 포함하는 메르스 코로나바이러스의 예방 또는 치료용 조성물 | |
US20090023184A1 (en) | Novel Tachykinin Peptides, Precursor Peptides Thereof And Genes Encoding The Same | |
KR101844481B1 (ko) | 기억력 향상 효과를 가지는 펩타이드 | |
WO2019059476A1 (ko) | 혈관신생 억제용 펩타이드 및 이의 용도 | |
KR20180046392A (ko) | 네오아가로올리고당을 포함하는 관절염 예방, 개선 또는 치료용 조성물 | |
US20220125889A1 (en) | Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease | |
KR101923062B1 (ko) | 네오아가로올리고당을 포함하는 골다공증 예방, 개선 또는 치료용 조성물 | |
WO2020111501A1 (ko) | Aeg-1 s298d을 유효성분으로 포함하는 파킨슨 질환 예방 또는 치료용 조성물 | |
WO2023224357A1 (ko) | 혈뇌장벽을 통과하는 폴리펩타이드 및 이의 용도 | |
CA2202496A1 (en) | Neurotrophic peptides of activity dependent neurotrophic factor | |
KR20200077448A (ko) | 니코틴아마이드를 포함하는 두개쇄골이형성증 연관 치아맹출부전증의 개선, 예방 또는 치료용 조성물 | |
KR20180037792A (ko) | 구제역 바이러스 백신 조성물 | |
Calza et al. | Nerve growth factor in the central nervous system: more than neuron survival. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 15482752 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2965840 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12017550079 Country of ref document: PH |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16879083 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017546737 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2016879083 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016376059 Country of ref document: AU Date of ref document: 20160503 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/006823 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201804902U Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018012527 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018120516 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 112018012527 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180619 |